Allist Pharmaceuticals Inc. (SHA: 688578), a Shanghai-based pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its AST2303, an oral small molecule epidermal growth factor (EGFR) inhibitor, for adult patients with advanced non-small cell lung cancer (NSCLC) that carries the EGFR C797S mutation.
Preclinical research has indicated that AST2303 possesses potent tumor cell inhibition and killing capabilities, demonstrating the ability to inhibit and reduce tumor size in animal models bearing tumors. The drug has also shown high selectivity for wild-type EGFR, suggesting a favorable safety profile. Additionally, AST2303 has exhibited efficient penetration of the blood-brain barrier, which could lead to effective drug exposure in the central nervous system and potentially enable the treatment or prevention of central nervous system metastasis in NSCLC patients.- Flcube.com
